Swiss multinational Roche may have entered the checkpoint inhibitor market behind other big pharma companies, but it is continuing to rack up promising initial results with its PD-L1 inhibitor, Tecentriq (atezolizumab) in a series of cancers, tangible evidence that it may be catching up fast with its competitors.
Roche's Tecentriq-Avastin Combo Improves PFS In Kidney Cancer Too
Top-line results from Roche's Phase III IMmotion151 study indicates the first-line use of a Tecentriq-Avastin combination has a significant effect on patients with advanced renal cancer who are PD-L1 expressers, but further details from the study will only become available in 2018.
More from Clinical Trials
More from R&D
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.